03 January 2017
: Case report
Pituitary Metastasis from Renal Cell Carcinoma: Description of a Case Report
Unusual clinical course, Challenging differential diagnosis
Chloé Wendel1ABCDEF, Marco Campitiello1ABCDE, Francesca Plastino1ABCDE, Nada Eid1ABCDE, Laurent Hennequin2ABCDE, Philippe Quétin3ABCDE, Raffaele Longo1ABCDEFG*DOI: 10.12659/AJCR.901032
Am J Case Rep 2017; 18:7-11
Abstract
BACKGROUND: Pituitary metastasis is uncommon, breast and lung cancers being the most frequent primary tumors. Renal cell carcinoma (RCC) is a rare cause of pituitary metastases, with only a few cases described to date.
CASE REPORT: We report a case of a 61-year-old man who presented with a progressive deterioration of visual acuity and field associated with a bitemporal hemianopsia. Two years ago, he underwent radical right nephrectomy for a clear cell RCC (ccRCC). The biological tests showed pan-hypopituitarism and diabetes insipidus. Brain MRI revealed a large sellar tumor lesion bilaterally infiltrating the cavernous sinuses, which was surgically resected. Histology confirmed a ccRCC pituitary metastasis. The patient received post-surgical radiotherapy. Considering the presence of concomitant extra-pituitary metastases, treatment with sunitinib was started, followed by several lines of therapy with axitinib, everolimus, and sorafenib because of tumor progression. The patient also presented with a pituitary tumor recurrence, which was treated by stereotaxic radiotherapy. He died five years after the initial diagnosis of RCC and 30 months after the diagnosis of the pituitary metastasis.
CONCLUSIONS: There are no standardized treatment guidelines for management of pituitary metastases. Pituitary surgery plays a role in symptom palliation, and it does not have any relevant impact on survival. Exclusive radiotherapy or stereotaxic radiotherapy could be an alternative to surgery in patients whose general condition is poor or who have concomitant extra-pituitary metastases.
Keywords: Angiogenesis Inhibitors, Carcinoma, Renal Cell, Pituitary Neoplasms
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.948268
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.948283
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947725
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947694
Most Viewed Current Articles
21 Jun 2024 : Case report
102,058
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
54,550
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
38,308
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
07 Jul 2023 : Case report
26,047
DOI :10.12659/AJCR.940200
Am J Case Rep 2023; 24:e940200